This site is intended for healthcare professionals only


Stepping down ICS therapy in COPD

Posted on: 16 Oct 2018

In most industrialised countries, approximately 40% of patients diagnosed with COPD are candidates for inhaled corticosteroids (ICS). And yet, prescribing rates can exceed 80%. This means that a lot of patients are being exposed to the risks associated with ICS. It also means that the cost of their care is unnecessarily high.

It is important to know whether and how ICS therapy can be safely stepped down.

Access the PCRS desktop helper ‘Evaluation of appropriateness of inhaled corticosteroid (ICS) therapy in COPD and guidance on ICS withdrawal’.

Stepping down ICS therapy in COPD

Media partners

Developed in partnership with

Funded by

Media partners:

The Primary Care Respiratory Academy has been developed and is produced by Cogora, the publisher of Pulse, Nursing in Practice, Healthcare Leader, Management in Practice and The Pharmacist working in partnership with PCRS.

All educational content for the website and videos has been initiated and produced by PCRS and Cogora.

The Primary Care Respiratory Academy is sponsored by Chiesi Ltd.